Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study

Next Previous
X
Search
Trial Profile

MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Dexamethasone; Dexamethasone; Dolasetron; Granisetron; Granisetron; Ondansetron; Ondansetron; Palonosetron; Palonosetron; Tropisetron; Tropisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms MyRisk
  • Sponsors Helsinn Healthcare SA

    • Most Recent Events

    • 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
    • 17 Apr 2024 Planned End Date changed from 30 Nov 2024 to 31 Dec 2024.
    • 17 Apr 2024 Planned primary completion date changed from 30 Apr 2024 to 31 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top